Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab + Durvalumab with TACE in Unresectable HCC
NCT06911255Phase 2Recruiting
- Sponsor
- Yoon Jun Kim
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab, durvalumab in hepatocellular carcinoma (HCC), sponsored by Yoon Jun Kim. Started Apr 2025; status: recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06911255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911255.